Aktieanalys

Egetis Therapeutics Q4: Approved in EU, launch in Germany in Q2 - Redeye

{newsItem.title}

Redeye Publicerad: 27 Feb 11:22

Egetis Therapeutics

Redeye returns with an updated view of Egetis Therapeutics following the Q4 report and the recent approval in the EU. 2025 looks like an interesting year -with a launch in EU and a likely US filing.

Länk till analysen i sin helhet: https://www.redeye.se/research/1083708/egetis-therapeutics-q4-approved-in-eu-launch-in-germany-in-q2?utm_source=finwire&utm_medium=RSS

Nyheter om Egetis Therapeutics

Läses av andra just nu

Om aktien Egetis Therapeutics

Senaste nytt